Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: VRC01, SC placebo for VRC01, IV placebo for VRC01; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more

Conditions: Degenerative Disc Disease
Interventions: NuQu, Placebo; Biological · Other
Lead sponsor: ISTO Technologies, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Santa Monica, California + 7 more

Conditions: Healthy Volunteers
Interventions: NoV Placebo-matching Saline, NoV GI.1/GII.4 Bivalent VLP Vaccine; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 4,748 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Great Lakes, Illinois

Conditions: Lumbar Disc Disease
Interventions: BRTX-100, Saline; Biological · Drug
Lead sponsor: BioRestorative Therapies; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more

Conditions: Parenteral Nutrition
Interventions: Numeta G16%E, Sodium Glycerophosphate Injection; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: 0.5mL Intramuscular Injection; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 392 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Overland Park, Kansas • Omaha, Nebraska • Rochester, New York + 1 more

Conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
Interventions: DCR-PHXC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Pain, Postoperative
Interventions: ropivacaine; Drug
Lead sponsor: Liberman, Eric, D.O.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: Prostate Cancer, Robotic Prostatectomy, Foley Catheter Discomfort
Interventions: Bupivacaine, Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo; Biological
Lead sponsor: Kara Chew; Other
Eligibility: 40 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Coronavirus Disease (COVID-19)
Interventions: V591, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Hollywood, Florida • Wichita, Kansas • Lexington, Kentucky + 1 more

Conditions: Solid Tumor Refractory to Standard Therapy
Interventions: SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day, SQ001 625mL/day, Saline 0.9%; Drug
Lead sponsor: Livzon Pharmaceutical Group Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Kidney Injury
Interventions: 0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions: 18-NaF PET, DCE-MRI, 18-FDG PET/CT; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Zoster
Interventions: Live attenuated herpes zoster vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee

Conditions: Ureter Injury
Interventions: Indigotindisulfonate sodium 0.8%, Saline injection 0.9%; Drug · Other
Lead sponsor: Prove pharm; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Albany, New York

Conditions: Infection, Human Immunodeficiency Virus
Interventions: 744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: 0.9% Sodium Chloride, Furosemide 40 mg; Drug
Lead sponsor: Adhish Agarwal; Other
Eligibility: 21 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Carcinoma, Hepatocellular
Interventions: PF-03446962, Best Supportive Care, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Shoulder Pain
Interventions: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide; Drug
Lead sponsor: Injury Care Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Genital Herpes Simplex Type 2
Interventions: GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: Elevated Lipoprotein(a), Cardiovascular Disease
Interventions: ISIS 681257, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more

Conditions: Major Advanced Solid Tumors Other Than Colorectal
Interventions: PM01183; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado • Chicago, Illinois

Conditions: Corneal Neovascularization, Corneal Graft Failure
Interventions: Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel; Drug
Lead sponsor: Reza Dana, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • New York, New York

Search by objective public record fields.

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication

Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Fluid Chloride and AKI in Cardiopulmonary Bypass

Imaging in MGUS, SMM and MM

ZOSTAVAX® in Renal Transplant Patients

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival